Investigational drug · Phase 2
BI 1569912
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Depressive Disorder, Major.
Phase 2Last checked: Nov 20, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
8
Any phase or sponsor naming "BI 1569912"
First trial start
2024
Mar 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 1569912", any sponsor or status.
Conditions studied
As listed on its trial records.
- Depressive Disorder, Major
Approved drugs for the same conditions: Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 1569912" as an intervention, largest first.
- A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicinePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06280235 · 243 participants · Start Mar 27, 2024 · Primary completion Feb 26, 2025
Drug: BI 1569912; Placebo · For: Depressive Disorder, Major
Sites: Tucson, Arizona; Oceanside, California; Orange, California · 52 sites in all
- A Study to Test Different Doses of BI 1569912 in People With DepressionPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06558344 · 225 participants · Start Oct 1, 2024 · Primary completion May 2, 2025
Drug: 5 mg BI 1569912; Placebo matching BI 1569912 and 2 more · For: Depressive Disorder, Major
Sites: Bellflower, California; Long Beach, California; Oceanside, California · 41 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04978506 · 83 participants · Start Sep 3, 2021 · Primary completion Jul 4, 2024
Drug: BI 1569912; Placebo · For: Healthy
Sites: Berlin, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT04445090 · 68 participants · Start Jul 21, 2020 · Primary completion Sep 10, 2021
Drug: BI 1569912; Placebo · For: Healthy
Sites: Berlin, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT04937829 · 59 participants · Start Jul 20, 2021 · Primary completion Nov 16, 2023
Drug: 5 mg BI 1569912; 20 mg BI 1569912 and 1 more · For: Depressive Disorder, Major
Sites: Garden Grove, California; Torrance, California; Miami, Florida · 10 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04958252 · 56 participants · Start Aug 5, 2021 · Primary completion Oct 30, 2023
Drug: BI 1569912; Placebo · For: Healthy
Sites: Tokyo, Sumida-ku, Japan
Boehringer IngelheimBoehringer Ingelheim
NCT06367153 · 18 participants · Start May 15, 2024 · Primary completion Aug 20, 2024
Drug: BI 1569912; Repaglinide and 2 more · For: Healthy
Sites: Edegem, Belgium
Boehringer IngelheimBoehringer Ingelheim
NCT06520553 · 8 participants · Start Aug 26, 2024 · Primary completion Oct 3, 2024
Drug: BI 1569912 (C-14); BI 1569912 (C-13) · For: Healthy
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials.
Cohen EA, Sanacora G, Watanabe K, et al. · Neuropsychopharmacology 2026
- Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials.
Hünnemeyer A, Ogama Y, De Crescenzo F, et al. · J Psychopharmacol 2026
- Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.
McIntyre RS, Sanacora G, Walling DP, et al. · Clin Pharmacol Ther 2025
Also in development for Depressive Disorder, Major
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- SeltorexantJNJ 42847922Phase 32 trials
Johnson & Johnson (Janssen) · Depressive Disorder, Major
- JNJ-89495120Phase 21 trial
Johnson & Johnson (Janssen) · Depressive Disorder, Major
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.